Literature DB >> 1680556

The management of the levodopa psychoses.

J H Friedman1.   

Abstract

Parkinson's disease (PD) is frequently associated with psychiatric problems. Depression generally responds to antidepressant medications or to electroconvulsive therapy (ECT). The nondepressive psychoses generally require a reduction in parkinsonian medications, or possibly a "drug holiday." In patients whose psychosis fails to respond to a reduction in medication or who cannot tolerate the worsening parkinsonism, an antipsychotic drug should be added. Clozapine is probably the drug of choice, with low potency neuroleptics being second-line options.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680556     DOI: 10.1097/00002826-199108000-00001

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  15 in total

1.  Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors:  P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Authors:  Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2011-06-28       Impact factor: 10.338

Review 3.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 4.  Acute behaviour disturbances.

Authors:  G G Lloyd
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

5.  Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease.

Authors:  D Brandstaedter; S Spieker; G Ulm; U Siebert; T E Eichhorn; J C Krieg; W H Oertel; K Eggert
Journal:  J Neurol       Date:  2005-04-01       Impact factor: 4.849

6.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 7.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

Review 9.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

Review 10.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.